Abstract
Objectives To determine if there is an association between survival rates in intensive care units (ICU) and occupancy of the unit on the day of admission.
Design National retrospective observational cohort study during the COVID-19 pandemic.
Setting 90 English hospital trusts (i.e. groups of hospitals functioning as single operational units).
Participants 6,686 adults admitted to an ICU in England between 2nd April and 1st December, 2020 (inclusive), with presumed or confirmed COVID-19, for whom data was submitted to the national surveillance programme and met study inclusion criteria.
Interventions N/A
Main Outcomes and Measures A Bayesian hierarchical approach was used to model the association between hospital trust level (mechanical ventilation compatible) bed occupancy, and in-hospital all-cause mortality. Results were adjusted for unit characteristics (pre-pandemic size), individual patient-level demographic characteristics (age, sex, ethnicity, time-to-ICU admission), and recorded chronic comorbidities (obesity, diabetes, respiratory disease, liver disease, heart disease, hypertension, immunosuppression, neurological disease, renal disease).
Results 121,151 patient-days were observed, with a mortality rate of 20.8 per 1,000 patient days. Adjusting for patient-level factors, mortality was higher for admissions during periods of high occupancy (>85% occupancy versus the baseline of 45 to 85%) [OR 1.18 (95% posterior credible interval (PCI): 1.00 to 1.38)]. In contrast, mortality was decreased for admissions during periods of low occupancy (<45% relative to the baseline) [OR 0.79 (95% PCI: 0.69 to 0.90)].
Conclusion and Relevance Increasing occupancy of beds compatible with mechanical ventilation, a proxy for operational strain, is associated with a higher mortality risk for individuals admitted to ICU. Public health interventions (such as expeditious vaccination programmes and non-pharmaceutical interventions) to control both incidence and prevalence of COVID-19, and therefore keep ICU occupancy low in the context of the pandemic, are necessary to mitigate the impact of this type of resource saturation.
Summary Box
What is already known on this topic
What is already known on this topic Pre-pandemic, higher occupancy of intensive care units was shown to be associated with increased mortality risk. However, there is limited data on the extent to which occupancy levels impacted patient outcomes during the COVID-19 pandemic, especially in light of the mobilisation of significant additional resources. A recent study from Belgium reported a 42% higher mortality during periods of ICU surge capacity deployment, although in the analysis surge capacity was evaluated only as a binary variable, and notably this contradicts earlier results from smaller studies in Australia and Wales, where no association between ICU occupancy and mortality was identified.
What this study adds
What this study adds The results of this study suggest that survival rates for patients with COVID-19 in intensive care settings appears to deteriorate as the occupancy of (surge capacity) beds compatible with mechanical ventilation (a proxy for operational pressure), increases. Moreover, this risk doesn’t occur above a specific threshold, but rather appears linear; whereby going from 0% occupancy to 100% occupancy increases risk of mortality by 69% (after adjusting for relevant individual-level factors). Furthermore, risk of mortality based on occupancy on the date of recorded outcome is even higher; OR 2.98 (95% posterior credible interval: 2.33 – 3.83). As such, this national-level cohort study of England provides compelling evidence for a relationship between occupancy and critical care mortality, and highlights the needs for decisive action to control the incidence and prevalence of COVID-19.
Competing Interest Statement
SJV declares funding from IQVIA and Microsoft. BAM is an employee of the Wellcome Trust, and holds a Wellcome funded honorary post at University College London for the purposes of carrying out independent research; the views expressed in this manuscript do not necessarily reflect the views or position of the Wellcome Trust. All other authors declare no competing interests.
Clinical Trial
NA
Funding Statement
This study received no direct funding. The individual authors' funder had no role in the design of the study, the analysis, or the formulation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the Warwick Biosciences Research Ethics Committee (BSREC 120/19-20-V1.1) and sponsorship is being provided by University of Warwick (SOC.28/19-20).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ Joint Senior Authors
In this revised version of the original pre-print we have extended date range up to and including the 1st of December (the end of the second wave of non-pharmaceutical interventions in England), introducing another 2000 people admitted to intensive care units across England into the analysis.
Data Availability
Data cannot be shared publicly as it was collected by Public Health England (PHE) as part of their statutory responsibilities, which allows them to process patient confidential data without explicit patient consent. Data utilised in this study were made available through an agreement between the University of Warwick and PHE. Individual requests for access to CHESS data are considered directly by PHE (contact via covid19surv{at}phe.gov.uk).
